A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
Jaden Brandt
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (66)
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. 2023-01-01 · Expand citations
- Applying Lessons From Cannabis to the Psychedelic Highway 2022-06-17 · Expand citations
- Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy. 2022-05-14 · Expand citations
- Policy in focus: Is psilocybin the next cannabis? 2021-11-15 · Expand citations
- Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment 2021-04-29 · Expand citations
- Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin. 2020-07-02 · Expand citations
- Production Options for Psilocybin: Making of the Magic. 2019-01-18 · Expand citations
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. 2016-12-01 · Expand citations
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 2016-07-01 · Expand citations
- Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. 2015-03-01 · Expand citations
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. 2014-11-01 · Expand citations
- Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. 2011-01-01 · Expand citations
- Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. 2006-11-01 · Expand citations
- OpenAlex W1973613743
- OpenAlex W2025257299
- OpenAlex W2045595721
- OpenAlex W2072522556
- OpenAlex W2103048557
- OpenAlex W2108846054
- OpenAlex W2114183716
- OpenAlex W2132011757
- OpenAlex W2140018908
- OpenAlex W2166952073
- OpenAlex W2234681180
- OpenAlex W2290816644
- OpenAlex W2316694232
- OpenAlex W2504773786
- OpenAlex W2610144880
- OpenAlex W2753625084
- OpenAlex W2757917284
- OpenAlex W2781488255
- OpenAlex W2792164490
- OpenAlex W2797803761
- OpenAlex W2802638831
- OpenAlex W2808301300
- OpenAlex W2895986834
- OpenAlex W2897760082
- OpenAlex W2899027265
- OpenAlex W2911226174
- OpenAlex W2923355729
- OpenAlex W2969818417
- OpenAlex W2969964941
- OpenAlex W2971496197
- OpenAlex W3008649055
- OpenAlex W3037462750
- OpenAlex W3105653790
- OpenAlex W3106850904
- OpenAlex W3112173414
- OpenAlex W3135595060
- OpenAlex W3137839889
- OpenAlex W3165796092
- OpenAlex W3187215861
- OpenAlex W3193605940
- OpenAlex W3199682754
- OpenAlex W3202565570
- OpenAlex W3211291416
- OpenAlex W4200571248
- OpenAlex W4206147469
- OpenAlex W4220914378
- OpenAlex W4220928043
- OpenAlex W4223998676
- OpenAlex W4225857844
- OpenAlex W4229029658
- OpenAlex W4229333009
- OpenAlex W4229336530